tetano
Editor, Senior Moderator
Clin Appl Thromb Hemost
. 2022 Jan-Dec;28:10760296221141449.
doi: 10.1177/10760296221141449.
The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection
Amine Bouchlarhem[SUP] 1 2 [/SUP], Soumia Boulouiz[SUP] 1 2 [/SUP], Ghizlane El Aidouni[SUP] 1 3 [/SUP], Houssam Bkiyar[SUP] 1 3 [/SUP], Zakaria Bazid[SUP] 1 2 [/SUP], Nabila Ismaili[SUP] 1 2 [/SUP], Brahim Housni[SUP] 1 3 [/SUP], Noha El Ouafi[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
Objective: Our objective in this study was to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotics on protection against these complications.
Methods: We conducted a single-center retrospective study of 158 patients with heart disease admitted to an intensive care unit for severe SARS-COV-2 infection. In order to determine the predictive factors, we used logistic regression analysis.
Results: Out of 158 patients, 22 were complicated by a thrombo-embolic event (13.9%), mean age of our population 64.03 (SD = 15.27), with a male predominance of 98 (62%). For the predictive factors of thromboembolic complications, and after multivariate analysis, we find the short duration of hospitalization (OR = 0.92; 95%CI (0.863-0.983), P = .014, previous use of antithrombotic drugs ((OR = 0.288, 95%CI (0.091-0.911), P = .034 for antiplatelet agents) and (OR = 0.322, 95% CI (0, 131-0.851), P = .021) for anticoagulants) as protective factors, and admission thrombocytosis as a risk factor (OR = 4.58, 95%CI (1.2-10.627), P = .021). D-dimer was not detected as a risk factor, and this can be explained by the characteristics of our population. Although prior use of antithrombotic drugs protects against thromboembolic complications during severe infection, there was no benefit in mortality.
Conclusion: Prior use of antithrombotic drugs is a protective factor against thromboembolic complications in patients with a history of heart disease but without effect on mortality.
Keywords: Covid-19; Inflammation; antithrombotic therpay; cardiovascular disease; prior use; thrombo-embolic events.
. 2022 Jan-Dec;28:10760296221141449.
doi: 10.1177/10760296221141449.
The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection
Amine Bouchlarhem[SUP] 1 2 [/SUP], Soumia Boulouiz[SUP] 1 2 [/SUP], Ghizlane El Aidouni[SUP] 1 3 [/SUP], Houssam Bkiyar[SUP] 1 3 [/SUP], Zakaria Bazid[SUP] 1 2 [/SUP], Nabila Ismaili[SUP] 1 2 [/SUP], Brahim Housni[SUP] 1 3 [/SUP], Noha El Ouafi[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 36514250
- DOI: 10.1177/10760296221141449
Abstract
Objective: Our objective in this study was to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotics on protection against these complications.
Methods: We conducted a single-center retrospective study of 158 patients with heart disease admitted to an intensive care unit for severe SARS-COV-2 infection. In order to determine the predictive factors, we used logistic regression analysis.
Results: Out of 158 patients, 22 were complicated by a thrombo-embolic event (13.9%), mean age of our population 64.03 (SD = 15.27), with a male predominance of 98 (62%). For the predictive factors of thromboembolic complications, and after multivariate analysis, we find the short duration of hospitalization (OR = 0.92; 95%CI (0.863-0.983), P = .014, previous use of antithrombotic drugs ((OR = 0.288, 95%CI (0.091-0.911), P = .034 for antiplatelet agents) and (OR = 0.322, 95% CI (0, 131-0.851), P = .021) for anticoagulants) as protective factors, and admission thrombocytosis as a risk factor (OR = 4.58, 95%CI (1.2-10.627), P = .021). D-dimer was not detected as a risk factor, and this can be explained by the characteristics of our population. Although prior use of antithrombotic drugs protects against thromboembolic complications during severe infection, there was no benefit in mortality.
Conclusion: Prior use of antithrombotic drugs is a protective factor against thromboembolic complications in patients with a history of heart disease but without effect on mortality.
Keywords: Covid-19; Inflammation; antithrombotic therpay; cardiovascular disease; prior use; thrombo-embolic events.